Portal venous hyperinsulinemia does not stimulate gut glucose absorption in the conscious dog.
The purpose of the present study was to assess whether physiological portal vein hyperinsulinemia stimulates gut glucose absorption in vivo. Chronically catheterized (femoral artery, portal vein, inferior vena cava, and proximal and distal duodenum) and instrumented (Doppler flow probe on portal vein) insulin (INS, 2 mU.kg(-1).min(-1), n = 6) or saline (SAL, n = 5) infused dogs were studied during basal (30 minutes) and experimental (90 minutes) periods. Arterial and portal vein plasma insulin were 3.3- and 3.2-fold higher, respectively, throughout the study in INS compared to SAL. An intraduodenal glucose infusion of 8 mg.kg(-1).min(-1) was initiated at t = 0 minutes. At t = 20 and 80 minutes, a bolus of 3-O-[3H]methylglucose (MG) and L-[14C]glucose (L-GLC) was injected intraduodenally. Phloridzin, an inhibitor of the Na+ -dependent glucose transporter (SGLT1), was infused from t = 60 to 90 minutes in the presence of a peripheral isoglycemic clamp. Net gut glucose output (NGGO) was 5.2 +/- 0.6 and 4.6 +/- 0.8 mg.kg(-1).min(-1) in INS and SAL, respectively, from t = 20 to 60 minutes. Transporter-mediated absorption was 87% +/- 2% of NGGO in both INS and SAL. Passive gut glucose absorption was 13% +/- 2% of NGGO in both INS and SAL. Phloridzin-induced inhibition of transporter-mediated absorption completely abolished passive absorption of L-GLC in both groups. This study shows that under physiological conditions, a portal vein insulin infusion that results in circulating hyperinsulinemia does not increase either transporter-mediated or passive absorption of an intraduodenal glucose load.
Camacho
Raul C
RC
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashille, TN 37232, USA.
Denny
Joshua C
JC
Pencek
R Richard
RR
Koyama
Yoshiharu
Y
Lacy
D Brooks
DB
James
Freyja D
FD
Wasserman
David H
DH
D000465:Algorithms; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004064:Digestive System / Q000378:metabolism*; D004285:Dogs; D004386:Duodenum / Q000378:metabolism; D004837:Epinephrine / Q000097:blood; D005260:Female; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000378:metabolism*; D006854:Hydrocortisone / Q000097:blood; D006946:Hyperinsulinism / Q000097:blood*; D007328:Insulin / Q000097:blood; D007408:Intestinal Absorption / Q000502:physiology*; D007700:Kinetics; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D009004:Monosaccharide Transport Proteins / Q000378:metabolism; D009638:Norepinephrine / Q000097:blood; D010695:Phlorhizin / Q000494:pharmacology; D011169:Portal Vein / Q000378:metabolism*; D012039:Regional Blood Flow / Q000502:physiology; D051269:Sodium-Glucose Transporter 1
D001786:Blood Glucose; D007328:Insulin; D008562:Membrane Glycoproteins; D009004:Monosaccharide Transport Proteins; D051269:Sodium-Glucose Transporter 1; D005934:Glucagon; D010695:Phlorhizin; D005947:Glucose; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine